Teopranitol, a coronary vasodilator that was studied for the treatment of the acute myocardial ischemia. Animal experiments have shown that this compound stimulated the release of prostacyclin (PGI2)-like antiplatelet activity. However, the development of teopranitol was discontinued.

Cevoglitazar is a dual agonist for the peroxisome proliferator-activated receptor (PPAR)-alpha and -gamma subtypes. Cevoglitazar was as effective as pioglitazone at improving glucose tolerance, normalizes intramyocellular lipids and reduces body weight gain and adiposity, independent of food intake. Metabolic profiling showed that in the muscle cevoglitazar improves the lipid profile via both PPARα‐ and PPARγ‐mediated mechanisms. Cevoglitazar only induced small changes to the lipid composition of visceral fat. In subcutaneous fat, however, cevoglitazar induced changes similar to those observed with fenofibrate suggesting export of fatty acids from this depot.

Sanofi aventis developed saredutant (also known as SR 48968C) as a tachykinin neurokinin-2 (NK2) receptor antagonist for the treatment of depressive disorders and generalized anxiety disorder. This drug participated in phase III clinical trials in patients with a generalized anxiety disorder and as Combination Treatment for major depressive disorder, however, the drug failed to meet efficacy endpoints. It is known that NK-2 receptor mediates airway obstruction that is why saredutant was studied as a potential treatment of asthma. However, all studies of the drug were discontinued.

LY 300502 is now called bexlosteride was developed as an inhibitor of the human-specific type I-selective steroid 5alpha-reductase. This drug was studied for patients with prostate cancer, however, has never been marketed.

Morocromen is an oxobenzopyranyl derivative patented by Troponwerke Dinklage und Co. as the coronary dilating agent.

Menogaril is a semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin. Biochemical studies indicated that, in comparison to doxorubicin, menogaril is bound weakly to DNA, inhibits RNA synthesis less, and has different cell cycle phase-specific cytotoxicity. Menogaril acts as a cleavable complex-stabilizing topoisomerase II inhibitor. Menogaril has been studied in the treatment of various cancers.

LECIMIBIDE is an intestinally active acyl-CoA:cholesterol acyltransferase inhibitor. It was under development as an antihyperlipidemic drug. However, information about the current status of this compound is not available.

Gadopenamide is an MRI contrast agent that was introduced in 1991. It has been investigated as a potential clinical contrast medium by Schering AG (Germany), but has never been used as such.